Physician profile
David B Ross
NPI 1063630861
$8,209.72
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $3,054 · 2021: $3,010 · 2022: $998 · 2023: $16.73 · 2024: $20.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $36.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $36.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $1,369.55 | 2020-2022 | |
| Ucb, INC. | $1,047.49 | 2019-2022 | |
| Eisai INC. | $631.72 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $611.38 | 2021 | |
| Abbvie INC. | $556.08 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $461.74 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $413.36 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $313.52 | 2020-2022 | |
| Amgen INC. | $304.86 | 2019-2022 | |
| Emd Serono, INC. | $257.97 | 2019-2021 | |
| Greenwich Biosciences, INC. | $219.89 | 2019-2021 | |
| Allergan, INC. | $187.02 | 2019-2020 | |
| Lilly USA, LLC | $177.78 | 2019-2021 | |
| Sk Life Science, INC. | $167.79 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $156.09 | 2019-2021 |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.